Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 6:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Stereotactic Body Radiotherapy Clear all
Recruiting Phase 2 Interventional

Study of PSMA PET/MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer

NCT04402151
View directory record Official record
Conditions
Prostate Cancer
Interventions
PSMA PET/MR - Gallium-68 labeled PSMA-HBED-CC, Stereotactic Body Radiation Therapy (SBRT)
Drug · Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
21 Years to 90 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Sep 28, 2026, 6:12 PM EDT
Recruiting Phase 2 Interventional

Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell Carcinoma

NCT07223541
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma
Interventions
Cemiplimab 350 MG Intravenous Solution, Fianlimab 1600 MG Intravenous Solution
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Sep 28, 2026, 6:12 PM EDT
Recruiting Phase 2 Interventional

Radioembolization Versus External Radiation Therapy

NCT07530172
View directory record Official record
Conditions
Heptocellular Cancer
Interventions
Transarterial Radioembolization, Stereotactic Body Radiation Therapy (SBRT)
Radiation
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 28, 2026, 6:12 PM EDT
Terminated No phase listed Observational

Circulating Tumor Cells in Prostate Cancer Patients

NCT01414712
View directory record Official record
Conditions
Prostate Cancer
Interventions
Blood Drawing
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 2 Interventional Results available

Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer

NCT02701400
View directory record Official record
Conditions
Recurrent Small Cell Lung Carcinoma
Interventions
Durvalumab, Hypofractionated Radiation Therapy, Stereotactic Body Radiation Therapy, Tremelimumab
Biological · Radiation
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 1 Interventional

Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer

NCT03122496
View directory record Official record
Conditions
Metastatic Anaplastic Thyroid Cancer
Interventions
durvalumab, tremelimumab, Stereotactic Body Radiotherapy (SBRT)
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Sep 28, 2026, 6:12 PM EDT
Withdrawn Phase 2 Interventional

SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients

NCT03126461
View directory record Official record
Conditions
Melanoma, Metastatic Melanoma
Interventions
SAbR, Ipilimumab, Nivolumab
Radiation · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Not applicable Interventional Results available

Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer

NCT01540994
View directory record Official record
Conditions
Prostatic Neoplasm
Interventions
Radiation Therapy
Radiation
Lead sponsor
Sharp HealthCare
Other
Eligibility
50 Years to 90 Years · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Sep 28, 2026, 6:12 PM EDT
Recruiting Phase 2 Interventional

A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer

NCT06130280
View directory record Official record
Conditions
Colorectal Cancer, Liver Metastases
Interventions
MR Guided Single Fraction Stereotactic Body Radiation Therapy (SBRT)
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 28, 2026, 6:12 PM EDT
Terminated Phase 1 Interventional

Phase I Stereotactic Body Radiation for Metastatic or Recurrent Platinum-Resistant Ovarian Cancer

NCT01494012
View directory record Official record
Conditions
Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Malignant Tumor of Peritoneum, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor
Interventions
stereotactic body radiation therapy, positron emission tomography, computed tomography, questionnaire administration, fludeoxyglucose F 18
Radiation · Procedure · Other + 1 more
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Sep 28, 2026, 6:12 PM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Study of OBP-301 (Telomelysin™) in Combination With Pembrolizumab and SBRT in Patients With HNSCC With Inoperable, Recurrent or Progressive Disease

NCT04685499
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma With Inoperable Recurrent or Progressive Disease
Interventions
OBP-301, Pembrolizumab
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 2 Interventional Results available

Hypofractionated Stereotactic Body Radiation Therapy (SBRT)

NCT01288534
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation Therapy
Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Sacramento, California • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 23, 2017 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 1 Interventional

Stereotactic Boost and Long-Term Androgen Deprivation for Adenocarcinoma of the Prostate

NCT02064036
View directory record Official record
Conditions
Adenocarcinoma of the Prostate
Interventions
Stereotactic Radiosurgical Boost, Casodex, Leuprolide
Radiation · Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Sep 28, 2026, 6:12 PM EDT
Recruiting Phase 1 Interventional

Trial of Oligometastasis SBRT With Immediate, Simulation-Free Treatment Delivery (OLIGO-SWIFT)

NCT07079098
View directory record Official record
Conditions
Oligometastasis, Oligometastatic Disease
Interventions
Simulation-free workflow, SBRT
Other · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Sep 28, 2026, 6:12 PM EDT
Terminated Phase 2 Interventional Results available

Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC

NCT04786093
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Stereotactic radiation therapy, Durvalumab
Radiation · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Sep 28, 2026, 6:12 PM EDT
Terminated Not applicable Interventional

Daily vs. Non-Daily SBRT for NSCLC

NCT03624907
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Daily Stereotactic Body Radiotherapy, Non-Daily Stereotactic Body Radiotherapy
Radiation
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Gainesville, Florida • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 3, 2021 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 2 Interventional Results available

Stereotactic Body Radiation for Prostate Oligometastases

NCT02680587
View directory record Official record
Conditions
Prostate Cancer, Oligometastases
Interventions
SBRT
Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Sep 28, 2026, 6:12 PM EDT
Completed Phase 1Phase 2 Interventional

Extracranial Stereotactic Radiosurgery in Treating Patients With Solid Tumors

NCT00311597
View directory record Official record
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
Radiosurgery
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Sep 28, 2026, 6:12 PM EDT
Withdrawn Phase 2 Interventional

Non-Invasive Cervical Cancer Radiotherapy for Stage IB-IVB

NCT03146039
View directory record Official record
Conditions
Cervical Cancer, Cervical Cancer Stage, Cervical Cancer Stage IB2, Cervical Cancer Stage IB1, Cervical Cancer Stage I, Cervical Cancer Stage IB, Cervical Cancer Stage II, Cervical Cancer Stage IIa, Cervical Cancer, Stage IIB, Cervical Cancer, Stage III, Cervical Cancer Stage IIIB, Cervical Cancer Stage IIIA, Cervical Cancer Stage Iv, Cervical Cancer Stage IVA, Cervical Cancer Stage IVB
Interventions
Radiation Therapy
Radiation
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 28, 2026, 6:12 PM EDT
Recruiting Phase 2 Interventional

Definitive Radiation for High-Risk Spine Metastases

NCT06165419
View directory record Official record
Conditions
Metastatic Cancer, Metastatic Lung Cancer, Metastatic Breast Cancer, Metastatic Tumor, Metastatic Tumor of Bone, Metastatic Tumor to the Spine, Spine Metastases, Metastasis
Interventions
SBRT to the spine
Radiation
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Sep 28, 2026, 6:12 PM EDT
Active, not recruiting Phase 2 Interventional Results available

An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer

NCT05500092
View directory record Official record
Conditions
Resectable Stage IIA to IIIB Non-small Cell Lung Cancer
Interventions
Nivolumab, (8gy x 3), Platinum Doublet
Drug · Radiation
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
4
States / cities
St Louis, Missouri • The Bronx, New York • White Plains, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 28, 2026, 6:12 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Accelerated Partial Breast Irradiation (APBI) Using Stereotactic Body Radiation Therapy (SBRT)

NCT04985032
View directory record Official record
Conditions
Ductal Carcinoma in Situ, Invasive Ductal Carcinoma of Female Breast
Interventions
stereotactic body radiation therapy
Radiation
Lead sponsor
RPCR, Inc.
Other
Eligibility
50 Years to 100 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
2
States / cities
Stuart, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 4, 2022 · Synced Sep 28, 2026, 6:12 PM EDT
Withdrawn Phase 2 Interventional

Study of Neoadjuvent Chemotherapy Followed by SBRT in Patients With Resectable and Borderline Resectable Pancreatic Cancer

NCT04130399
View directory record Official record
Conditions
Pancreatic Cancer, Pancreatic Adenocarcinoma
Interventions
Stereotactic Body Radiation Therapy (SBRT), FOLFIRINOX
Radiation · Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 16, 2019 · Synced Sep 28, 2026, 6:12 PM EDT
Active, not recruiting Phase 1 Interventional

Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer After Undergoing Surgery

NCT01923506
View directory record Official record
Conditions
Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer
Interventions
stereotactic body radiation therapy, quality-of-life assessment, laboratory biomarker analysis
Radiation · Procedure · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
19 Years and older · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 28, 2026, 6:12 PM EDT